BioSpace News Archive

Policy

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

HUTCHMED Limited announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors.

May 2, 2022
·
9 min read
Biotech Beach

Helixmith Announces VM202 (Engensis®) Presentation at New York Academy of Sciences “Advances in Pain” Meeting on May 3, 2022

Helixmith, a gene therapy company based in Seoul, Korea and San Diego, CA, announced an upcoming presentation on their lead plasmid DNA product, Engensis at the NYAS Advances in Pain Meeting on May 3, 2022.

May 2, 2022
·
4 min read
Biotech Bay

IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma

IDEAYA Biosciences, Inc. announced that the U.S. Food and Drug Administration has granted orphan-drug designation to darovasertib, a potential first-in-class protein kinase C inhibitor, for the treatment of uveal melanoma.

May 2, 2022
·
3 min read
Pharm Country

Teleflex to Host Analyst & Investor Day on May 20, 2022

Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced that the Company will host an Analyst & Investor Day on Friday, May 20, 2022 in New York City.

May 2, 2022
·
2 min read
Business

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Bright Minds Biosciences today announced the formation of its Scientific Advisory Board (“SAB”).

May 2, 2022
·
9 min read
FDA

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine

Orphalan SA today announces approval of Cuvrior™, a new salt of trientine (trientine tetrahydrochloride) by the United States Food and Drug Administration (FDA). Cuvrior™ is approved for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.

May 2, 2022
·
3 min read
Pharm Country

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

Zynerba Pharmaceuticals , Inc. presented a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, held April 28-30, 2022, in New Orleans, La., and virtually.

May 2, 2022
·
5 min read
Pharm Country

HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately.

May 2, 2022
·
4 min read
Genetown

Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

Decibel Therapeutics announced today that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held virtually and in Washington D.C. May 15-19, 2022.

May 2, 2022
·
2 min read
NANO-X IMAGING LTD Files 2021 Annual Report on Form 20-F

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission on May 2, 2022.

May 2, 2022
·
1 min read